In partnership with a St. Louis medical marijuana dispensary, data startup Abide Assay is running a pilot to test its algorithm and as a proof-of-concept to predict the effects of medical marijuana products.
Marijuana has compounds, cannabinoids and terpenes, that can be measured and quantified in every batch of marijuana or edible. These compounds have effects, but when it comes to treating specific conditions patients and healthcare providers don’t have guidance about which compounds and concentration is effective.
Abide Assay is building on the work of Dr. Dustin Sulak D.O. (of healer.com) who is studying the effects of specific compounds, and Abide is putting in place a post-consumption survey system to pull in more data from patients about their experience.
Chad Carpenter, Abide Assay CEO
“The questions have been developed with a clinical director as well as a behavioral scientist at SLU, and we’re going to run the pilot for about a month,” CEO Chad Carpenter told the 4thEst8. “After cultivating the phenotype of the product to be evaluated.”
The pilot is scheduled to run in November in partnership with St. Louis area dispensary, Swade. Carpenter says he and his co-founder are working part-time on Abide while it is pre-revenue and in customer discovery. They have an office at the CIC in St. Louis, and started business operations in June 2021 after parting ways with a different concern that started in 2020.
“The other guys were wanting to go make an app, and we were like ‘hey, we really need to make sure this data is sound,” Carpenter said. “We believe that there are interfaces that we can integrate into rather than have to build an app ourselves.”
Links:
